Neuroimmunology and Neurological Symptoms of COVID-19

Wainford Michae^*
*Correspondence: Wainford Michae, Department of Medicine, New York Presbyterian Hospital--Weill/Cornell Medical School, New York, USA, Email:

Keywords

CNS • PNS • T cell • B cell • Vaccination • Treatment • Neuroimmunology • Molecular mimicry • COVID-19 • SARS-CoV-2

INTRODUCTION

The coronavirus disease 2019 (COVID-19) is caused by the singlestranded positive sense ribonucleic acid (ssRNA) virus known as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Since COVID-19 first appeared in Wuhan, China, in December 2019, it has had an impact on millions of individuals all over the world. It is to blame for the global pandemic. SARS-CoV-2 has developed a number of mutant versions with different infectiousness. Globally, SARS-CoV-2 has significantly increased disease burden and mortality rates. SARS-CoV-2 and COVID-19 have caused an international social and economic crisis as a result of the harm they pose to people's personal health and healthcare systems. Western countries with strong economies are successful in preventing SARS-CoV-2 by vaccination, whereas economically weaker nations are less successful due to a lack of vaccine availability. Additionally, the quality of care for COVID-19 patients varies significantly depending on a country's level of economic prosperity. There is a lack of assistance from wealthy nations for economically weaker countries as a result of the pandemic's tendency to strike people everywhere [1].

Description

A beta-coronavirus is SARS-CoV-2. The 16 non-structural proteins involved in viral replication are encoded by the positive ssRNA genome. Additionally, four structural proteins are present for the nucleocapsid, spikeglycoprotein, membrane and envelope. The receptor for SARS-CoV-2 absorption is angiotensin-converting enzyme 2 (ACE2). Heparan sulphates on the cell surface operate as co-factors. In order for ACE2 and cellular uptake to connect, the spike protein is crucial. Since ACE2 is expressed in a large number of bodily cells, SARS-CoV-2 can infect the majority of organs. The infected cell is where SARS-CoV-2 produces the virus. For SARS-CoV-2 cellular entrance, more receptors and host factors have been identified. The majority of cells in the body have ACE2 receptors, which facilitate SARS-CoV-2 absorption [2].

The lung is the organ most negatively impacted by SARS-CoV-2. SARSCoV- 2 infection results in an unusual kind of pneumonia that is primarily interstitial and has patchy infiltrates. In extreme circumstances, the lung may totally be damaged, depriving the body of oxygen. The SARS-CoV-2 virus can harm any tissue besides the lung. The tissue damage might result from a direct virus infection or indirectly from an immune response that is out of control, as is lower down and explained for the nervous system [3].

Hypoxia and CNS Damage

Severe CNS hypoxia can result from reduced oxygenation brought on by SARS-CoV-2 induced pneumonia in COVID-19. Severe CNS hypoxia has been seen in a number of patients who have died from COVID-19. Acute hypoxicischemic damage with neuronal loss and apoptotic neurons are present. This type of CNS injury is a result of significantly decreased erythrocyte oxygenation in the lung and is unrelated to direct viral infection of the CNS or indirect effects mediated by the virus-induced immune response inside the CNS. The CNS becomes hypoxic as a result of the erythrocytes' decreased oxygenation. In addition to hypoxia, thromboembolic illness, inflammation and, to the greatest extent, alterations caused by hemodynamics were observed in CNS microthrombi at biopsy or autopsy [4,5].

Direct Effects of SARS-CoV-2 in CNS

There is proof that SARS-CoV-2 can exist in the central nervous system. According to some evidence, SARS-CoV-2 can infect a large number of CNSresident cells. A number of symptoms are brought on by cellular dysfunction brought on by SARS-CoV-2 infection in cells. For instance, SARS-CoV-2 infection of the olfactory bulb neurons will result in olfactory impairment (dysosmia). Additionally, infection of taste-sensing neurons will result in a decrease in taste perception (ageusia). Early signs of dysosmia and ageusia have been noted in COVID-19 individuals [5].

Vasculature and COVID-19

Endotheliitis can result from SARS-CoV-2 infection. SARS-CoV-2 infection-induced endotheliitis also affects the blood vessels in the CNS. Lymphocytes, neutrophils and macrophages build up in endothelium walls as a result of endotheliitis. Endotheliitis may have serious effects, ultimately leading to an ischemic stroke. Alternative SARS-CoV-2 damage pathways to both big and small cerebral arteries have been seen in COVID. Endotheliitis has been demonstrated to cause small vessel vasculitis in the heart. In COVID-19 disease, epicardial nerves may also be affected, showing signs of an inflammatory neuropathy and potentially leading to cardiac problems such myocardial damage and arrhythmias [6].

Chronic Fatigue Syndrome and COVID-19

Some patients who initially had COVID-19 later developed long-COVID-19, also known as post-COVID-19. These patients frequently experience severe weariness. Clinically, the illness resembles chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME). An energy failure at the cellular level, which can lead to fatigue and quick exhaustion, is strongly suggested to exist in CFS. Additionally, there are adjustments in some immune cell types that may lead to a rises in infection susceptibility. The stiffness of lymphocytes, the size of monocytes, the deformability and heterogeneity of neutrophils and the heterogeneity of erythrocytes were all observed to change. At this time, it is unknown precisely how COVID-19 causes later CFS. The diagnosis is primarily made based on clinical traits with atypical exhaustion present. There are currently no precise markers that enable a diagnosis to be made in a lab. Typically, a CSF examination does not reveal any standout characteristics. There are no medically approved medications that can be used to alleviate fatigue brought on by long-COVID-19 or post-COVID-19. Mild physical endurance training is used as treatment [7].

Treatment of COVID-19

Treatment options can be divided into those that aim to address organ damage brought on by SARS-CoV-2 infection and those that aim to treat viral virulence and viral replication of the virus. Remdesivir is a medication that prevents the replication of viruses. This medication was initially created to combat the Ebola virus. It has been demonstrated to be effective when administered quickly after SARS-CoV-2 infection. Increased efficacy could be shown when used with the Janus-kinase inhibitor baricitinib. Since dexamethasone reduces the host immunological response to the virus, it has been demonstrated to have positive benefits in COVID-19. The body may suffer catastrophic effects as a result of this host immunological reaction. Dexamethasone provides positive effects that are primarily noticeable in individuals who are critically ill and require mechanical ventilation. Increased mortality is seen in COVID-19 patients who are not significantly affected and do not need oxygen support. Tocilizumab, a monoclonal antibody (mAb) directed against the interleukin-6 receptor (IL-6R), has been demonstrated to have some positive effects in COVID-19 patients by lowering the need for mechanical support. Additionally, COVID-19's prognosis and survival were enhanced with Sarilumab, another mAb targeting IL-6R. In patients hospitalised with moderate to severe COVID-19, early treatment with anakinra, a mAb against the interleukin-1 receptor (IL-1R), guided by levels against soluble urokinase plasminogen activator receptor (suPAR), significantly decreased the risk of a worse clinical outcome at day 28 and decreased the length of hospital stay compared to placebo. Patients with COVID-19 have shown positive results from a variety of mAb directed against the SARS-CoV-2 spike protein. The probability of hospitalisation or mortality in at-risk, unvaccinated people with COVID-19 was decreased in patients treated early with this novel medication because malnupavir has anti-RNA polymerase activity [8-10].

Vaccination

The most effective way to stop SARS-CoV-2 and COVID-19 from spreading is by vaccination. At the end of 2020 and the beginning of 2021, the first vaccines were released. Since then, there has been a significant vaccination effort, with Israel and Great Britain having the most rapid vaccine programmes. Despite the fact that breakthrough infections have been noted, the vaccines have also demonstrated efficacy against SARS-CoV-2 mutant forms. Compared to cultures with low vaccination rates, those with high immunisation rates have improved their ability to contain the COVID-19 pandemic. Repeated vaccination methods have improved immunisation effectiveness and offered higher defence against new viral types. This immune response provides defence against SARS-CoV-2. The protein-based vaccinations cause the SARS-CoV-2 virus to be recognised by T- and B-cells. Neurological problems have been reported in vaccination-related cases. In general, those with prior COVID-19 experienced more negative effects from vaccination [10].

Conclusion

Numerous body organs are harmed by COVID-19, which is caused by SARS-CoV-2 infection. The infection and the ensuing immune reaction frequently attack the nervous system as well. There are few choices for treatment. The most effective strategy to avoid nervous system disease in relation to SARS-CoV-2 and COVID-19 is vaccination to stop the spread of SARS-CoV-2 and its variations. It's possible that SARS-CoV-2 and COVID-19's insights into the global population will help us comprehend how autoimmune diseases of the nervous system are generally induced.

References

1. Zhu, Na, Dingyu Zhang, Wenling Wang and Xingwang Li, et al. "A novel coronavirus from patients with pneumonia in China, 2019." N Eng J Med 382 (2020): 727-733.

Google Scholar, Crossref, Indexed at

2. Abdool Karim, Salim S and Tulio de Oliveira. "New SARS-CoV-2 variants -clinical, public health and vaccine implications." N Eng J Med 384 (2021): 1866-1868.

Google Scholar, Crossref, Indexed at

3. Malik, Yasmin A. "Properties of coronavirus and SARS-CoV-2." Malaysian J Pathol 42 (2020): 3-11.

Google Scholar, Indexed at

4. Yao, Hangping, Yutong Song, Yong Chen and Nanping Wu, et al. "Molecular architecture of the SARS-CoV-2 virus." Cell 183 (2020): 730-738.

Google Scholar, Crossref, Indexed at

5. Wang, Qihui, Yanfang Zhang, Lili Wu and Sheng Niu, et al. "Structural and functional basis of SARS-CoV-2 entry by using human ACE2." Cell 181 (2020): 894-904.

Google Scholar, Crossref, Indexed at

6. Yan, Renhong, Yuanyuan Zhang, Yaning Li and Lu Xia, et al. "Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2." Science 367 (2020): 1444-1448.

Google Scholar, Crossref, Indexed at

7. Zhou, Peng, Xing-Lou Yang, Xian-Guang Wang and Ben Hu, et al. "A pneumonia outbreak associated with a new coronavirus of probable bat origin." Nature 579 (2020): 270-273.

Google Scholar, Crossref, Indexed at

8. Wei, Jin, Mia Madel Alfajaro, Peter C. DeWeirdt and Ruth E. Hanna, et al. "Genome-wide CRISPR screens reveal host factors critical for SARS-CoV-2 infection." Cell 184 (2021): 76-91.

Google Scholar, Crossref, Indexed at

9. Shi, Heshui, Xiaoyu Han, Nanchuan Jiang and Yukun Cao, et al. "Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study." Lancet Infect Dis 20 (2020): 425-434.

Google Scholar, Crossref

10. Zhang, Nan, Xunhua Xu, Ling-Yan Zhou and Gang Chen, et al. "Clinical characteristics and chest CT imaging features of critically ill COVID-19 patients." Eur Radiol 30 (2020): 6151-6160.

Google Scholar, Crossref, Indexed at